Methodology of clinical trials in hand osteoarthritis: Conventional and proposed tools  by Lequesne, M.G. & Maheu, E.
Osteoarthritis and Cartilage (2000) 8, Supplement A, $64-$69 
© 2000 OsteoArthritis Research Society International 
doi: 10.1053/joca. 1999.0340, available online at http://www.idealibrary.com on | D IF --JI~=L ® 
1063-4584/00/0AOS64+06 $35.00/0 
Osteoarthritis 
and Cartilage 
Journal of the OsteoArthritis Research Society International 
~'=~A~.j~'~ i  OSTEOARTHRITI$ 
_ II!Ii:~I~ATi{/I; ,, 
Methodology of clinical trials in hand osteoarthritis: conventional and 
proposed tools 
M. G. Lequesne* and E. Maheul- 
*HSpital Leopold Bellan, 75014 Paris, France 
~fDepartment of Rheumatology B, HSpital Cochin, 75014 Paris, France 
Summary 
Background: Although very common, hand osteoarthritis (OA) is rarely the focus of clinical trials aimed at determining whether a drug is 
effective on its symptoms and/or anatomical progression. Besides the common difficulties met in trials in OA in general, the highly 
unpredictable course of hand OA presents specific challenges. However, hand OA is beginning to be considered as a potential model for the 
study of drugs in OA, since researchers now have at their disposal new clinical tools and radiological methods to assess with better accuracy 
and sensitivity either its symptomatic activity or its anatomical course. 
Method: The now well-known consensual recommendations for the design and conduct of clinical trials in OA are reviewed, and the specific 
clinical tools and radiological methods available for the assessment of hand OA detailed. Some specific recommendations for the design of 
clinical trials in hand OA and the selection of patients for such trials are proposed, taking into account the particularities of this location of OA. 
© 2000 OsteoArthritis Research Society International 
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Introduction 
Methodology of clinical trials in patients with osteoarthritis 
(OA) has improved over the last 7 years, mainly due to four 
meetings dedicated to arriving at a consensus followed by 
papers discussing trials in OA in general terms concerning 
the three main OA sites: hip, knee and hand. 1-4 This paper 
concentrates on studies specifically targeted at hand OA 
and expands upon our previous review. 5 
General considerations 
The first attempt to clarify and define slow acting drugs in 
OA (SADOA), either symptomatic (SY-SADOA) or disease- 
modifying drugs in OA (DMOADs instead of previously 
so-called 'chondroprotective' agents) was implemented by 
WHO and ILAR in 1992-1994. ~ Among the proposals were 
(1) the use of specific outcome measures for DMOADs, 
especially the measurement of the radiographic joint space 
width (JSW) and its loss over time, an assessment orig- 
inally proposed 6 and described in detail in 1995, ~ and (2) 
survival curve methodology to highlight the possible retar- 
dation of the joint space (JS) narrowing over 2-3 years. ~ 
These methodologies seem suitable to assess radio- 
graphic lesions or to count the newly affected fingers joints 
(F J) in hand OA over years in well designed, well 
controlled long-term trials. 
Several meetings (1995-1996) of the European Group 
for the Respect of Ethics and Excellence in Science 
(GREES) 2 and task force of the Osteoarthritis Research 
Society (now OARSI) in Washington (May 1996) 3 stated 
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that the distinction between fast and slow acting drugs in 
OA trials is not useful and proposed to establish two new 
classes: symptom-modifying drugs and structure-modifying 
drugs, the latter to be used instead of 'DMOADs', while 
maintaining the definition given in 1994: 'an agent able to 
prevent, stabilize, retard or even reverse cartilage (and 
other) lesions of OA in humans'. ~ Both the European 
GREES and the OARS group yielded many details on trial 
methodology for both classes of drug. 
Between these two meetings, the OMERACT III meeting 
(Cairns, Australia), led to a consensus from the audience 
on outcome measures of pivotal value ('core' set); of lesser 
value but strongly recommended ('middle core' set) and 
optional measures ('outer core' set) with regard to hip, knee 
and hand OA trials. Figure 1 summarizes the results. The 
report `) lacks detail and some difficulties arise when specific 
applications have to be drawn from the core set. One is the 
ambiguity of the statement 'imaging in trials >1 year' as an 
outcome measure. This comment is suitable for trials of 
possible disease- or structure-modifying drugs and their 
effect on the anatomical course of OA. On the "other hand, 
since a deleterious effect of a given NSAID (for instance, 
indomethacin) or of other drugs on cartilage remains an 
underlying hypothesis, this comment deals also with such a 
possible adverse reaction. However, the latter belongs to 
a distinct category of consequences recorded in a trial. 
Another difficulty may arise from the generality of the 
propositions, whereas given locations of OA, especially in 
the hand, requires certain adaptations. Nevertheless, the 
OMERACT III guidelines are concise and have utility 
although they are not detailed. These details may be found 
in the three other papers mentioned. 
Though hand OA does not appear, at first glance, to be 
as good a model for trials as knee and hip OA, the 
rheumatology community has progressively accepted that 
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Fig. 1. Osteoarthritis core concept (see text). Abbreviations: QOL: quality of life. Details (bottom) OTHER: performance based, flares, time 
to surgery, analgesic count. 
hand OA is a valuable model, beside hip and knee OA, 
provided some relevant alterations suitable to the particular 
profile of this location are made. We summarize below what 
appear to be, in our opinion, the main methodological 
characteristics (for a more detailed statement, please see 
Maheu et aLS). 
Specific considerations 
TRIALS OF SYMPTOM-MODIFYING DRUGS 
Diagnosis 
An American College of Rheumatology (ACR) sub- 
committee headed by Altman developed the only currently 
available set of validated classification criteria for hand OA 8 
(Table I). These criteria are largely accepted 2-4 and used. 
However, the following additional items, proposed in our 
first review, are strongly recommended: (1) to take into 
account the Heberden and/or Bouchard nodes of the fourth 
Table I 
The American College of Rheumatology criteria for the classifi- 
cation and reporting of hand OA 8 
1. Hand pain, aching, or stiffness 
and 
2. Hard tissue enlargement of 2 or more of 10 selected hand 
joints 
and 
3. Fewer than three swollen MCP joints 
and either 
4. (a) hard tissue enlargement of wo or more DIP joints 
or 
(b) deformity of two or more of 10 selected hand joints* 
*The 10 selected joints are the second and third DIP, second and 
third proximal interphalangeal nd the first carpometacarpal joints 
of both hands. This classification method yields a sensitivity of 
92% and a specificity of 98%. 
and fifth fingers (absent in the ACR set); (2) to obtain 
radiological OA image of the trapezometacarpal (TMC) joint 
if it appears to be clinically involved. Since X-rays are 
positive in only one-third of patients with Heberden's 
nodes, it can not be determined at this time whether 
radiologic images of other joints should be required. But 
we strongly recommend to perform an X-ray before entry; 
(3) to systematically consider some exclusions: rheumatoid 
and psoriatic arthritis, since each may cause OA or in the 
case of psoriatic arthritis, can be difficult o distinguish from 
erosive hand OA; chondrocalcinosis (TMC joint involve- 
ment); hemochromatosis; sequelae of algodystrophy of the 
hand and diabetes mellitus hand lesions, s 
Assessment  methods 
Pain assessment on a visual analog scale (VAS) or using 
the pain section of the AUSCAN (five questions; see 
below), patient's and physician's global assessments 
should be performed as usually. The value of sparing 
NSAID and/or analgesics consumption, as an outcome 
measure is still debated. Let us consider specific tools for 
hand OA. 
(1) The first validated functional index for hand OA was 
developed by Dreiser et aL and published in 1995. 9 It 
consists of a 10-item investigator-administered question- 
naire (Table II). The total score ranges theoretically from 0 
to 30, but in practice, usually varies from 2 to 18 points with 
regard to severity of symptoms of hand OA. Its valida- 
tion was based on the difference between patients with 
'painful' hand OA (i.e. pain on VAS>40 mm; mean score: 
12.41 +5.41), those with 'quiescent' hand OA (mean score: 
4.28-*3.87) and controls, defined by the absence of 
any disease involving the upper limbs (mean score: 
0.59+1.23). This index is valid, reproducible, and simple to 
use (2-3 min to administer). It has been used in several 
trials. Its sensitivity has recently been studied, as reported 
by Dreiser in the present issue. In the meantime, its 
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Table II 
Functional index for hand osteoarthritis developed by Dreiser et 
al. 9 (modified by the authors with the help of Paul Boulos-Haraoui) 
1. Are you able to turn a key in a lock? 
2. Are you able to cut meat with a knife? 
3. Are you able to cut cloth or paper with a pair of scissors? 
4. Are you able to lift a full bottle with the hand? 
5. Are you able to clench your fist? 
6. Are you able to tie a knot? 
7. For women: Are you able to sew? 
For men: Are you able to use a screwdriver? /
8. Are you able to fasten buttons? 
9. Are you able to write for a long period of time? 
10. Would you accept a handshake without reluctance? 
Scoring system: 0=possible without difficulty, 1=possible with 
slight difficulty, 2=possible with important difficulty, 3=impossible. 
inter-rater eproducibility was shown as good in 'painful' 
hand OA patients • (intraclass coefficient correlation 
(ICC)=0.82) and moderate in 'quiescent' hand OA 
(ICC=0.58). 1° The study of its external validity using pain 
on VAS assessment as a gold standard has shown 
a moderate correlation with pain (R=0.48), indicating that 
this index explores domains other than pain. 9 This func- 
tional index has been studied mostly in right-handed 
patients (92-96% of the patients in epidemiological 
studies). It should be noticed that question 10 refers 
specifically to handshakes, which always concern the right 
hand. However, its clinical relevance showed no difference 
according to the location of hand OA [either first TMC or 
interphalangeal (IP) joints OA]. 
(2) An important additional tool proposed by one of us 
(EM) in 1997 allows assessment of the notably intermittent 
and irregular active ('painful') and inactive phases of hand 
OA, which may involve up to 20 joints, making hand OA a 
polyarticular disease.The tool involves a weekly self- 
assessment scoring of the painful joints on a sketch pro- 
vided by the investigator (Fig. 2). Its preliminary validation 11 
on 54 'painful' patients over three months showed that, on 
average, 4-6 joints were painful (1-2 in intensity), 3-4 days 
per week. The score calculation is the product of pain 
intensity and the duration of pain flare for each joint divided 
by the number of days for each scoring period. The tool 
appears feasible, simple to explain (investigator's judge- 
ment) and easy enough to score by the patient. It measures 
pain flow over time and could be analysed in trials by the 
area under the curve (AUC) method. It is likely to be used 
along with other specific assessment tests, such as func- 
tional indices, either Dreiser's one or Bellamy's AUSCAN 12 
in future clinical trials in hand OA. 
(3) The AUSCAN. This second hand OA functional index 
has been developed by Bellamy using the framework 
previouslY used to develop the WOMAC indices. 12 It 
explores three different domains (pain, stiffness, function). 
This index is available only on request to Prof. N. Bellamy, 
Dept of Medicine, University of Queensland, Royal 
Brisbane Hospital, Herston, Brisbane, QId 4029, Australia. 
(4) Other outcome measures specific to hand OA are: 
(a) pain upon lateral pressure on proximal interphalan- 
geal (PIP) and distal interphalangeal (DIP) (antero- 
posterior on the TMC joint) graded on a three-point 
scale for intensity. This index of painful joint on 
articular pressure could be considered as a 'Ritchie 
index' for hand OA and provides interesting and 
relevant information. However, it has yet to be 
validated to show its metrologic properties; 
(b) Measurement of grip strength (PIP, DIP) or pinch 
strength (TMC); 
(c) Morning stiffness duration. The clinical validity and 
responsiveness of both grip strength and morning 
stiffness duration have not been established. 
To summarize, the primary Criterion may be either pain 
on VAS or a functional index. Using the Dreiser's index, a 
decrease of 3-4 points at the completion of the trial should 
be the desired endpoint. Duration of the trial depends 
on the class of drug being tested: with regard to the 
Sy-SADOAs, 6-9 months, sometimes up to 12 months 
(plus a 2-3 month post-therapeutic follow-up to assess the 
possible persistent effect) are desirable even when a 
fast-acting compound is evaluated. The long length of 
this type of study is necessary due to the irregularity 
of the painful phases which are often separated by a 
span of several weeks and with a minimum duration of 
2-3 months. 
Criteria for the selection of symptomatic or 'painful' 
hand OA patients 
The terms from the ACR criteria 'hand pain, aching or 
stiffness' (Table I) are not precise enough for hand OA 
trials: stiffness alone, without pain ('quiescent' inactive OA), 
would not be sufficient to assess results in a symptom- 
modifying drug trial. We propose additional criteria to 
specify the severity of symptoms defining 'painful' hand OA 
as follows (partly according to Lequesne et aL 1 and Maheu 
et aL s) 
(1) At least two IP and/or one TMC joint painful at 
entry. 
(2) At least two or three painful flares in a finger joint 
during the previous 12 months. 
(3) Pain during at least half of the days in the previous 
2 months. 
(4) Pain for at least 2 days before inclusion or pre- 
inclusion visit in a radiologically affected joint. 
(5) Pa~in achieving 40 mm or more on a VAS. 
(6) A Dreiser's index score >6 points. 
How many criteria (three, four or more) should be met? 
This is to be established in additional studies. 
TRIALS OF POTENTIAL STRUCTURE-MODIFYING DRUGS 
The primary criterion of a trial assessing structure- 
modifying drugs should be a measure of the changes in 
anatomical structure, i.e. today radiography. However, 
symptomatic effect of the drug must also be assessed. 
Therefore, some of the above mentioned outcome 
measures for symptoms should be selected and evaluated 
in parallel to disease modification throughout the trial 
duration. 
Diagnosis and patient selection 
In addition to the diagnostic criteria discussed previously, 
ar~ X-ray showing definite features of OA is necessary for 
baseline screening. 
As far as symptoms are concerned, since the trial will be 
of long duration (3-5 years), only a few 'flares' or periods of 
pain in two or more fingers or in TMC joint will be enough to 
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Fig. 2. Weekly self-assessment of painful joints i  hand OA. Sketch given to the patient to score weekly his/her painful joints: one half of 
circles is for the pain intensity (1 or 2, if pain); the other half for the number of painful days. If no pain, the patient does not record anything. 
assess symptomatic effect during the trial. A current painful 
phase, just before or at baseline, is, while desirable, not 
mandatory. 
Inclusion criteria derived from radiographic images 
should be fully defined. Patients with few moderate lesions 
(less than two IP joints involved) or, in contrast, with 
severely advanced hand OA (more than two-thirds of IP 
joints involved) ought not to be recruited. Likewise, con- 
cerning the stage of OA, the doubtful cases (osteophyte not 
clearly visible; no ascertained JS narrowing or no clear 
subchondral bone radiolucency) should be excluded as 
well as those with too highly advanced lesions: complete 
erosive hand OA, or JS completely collapsed in more than 
four IP (out of 18 IP in both hands). An alternative proposal 
could be to identify different subsets of hand OA patients 
according to the existence of erosive lesions at baseline 
and at the conclusion of the study. Patients with such 
erosive lesions should be analysed separately. However, 
the reader(s) should be blinded to the time-sequence order 
of X-rays. 
Radionuclide bone scanning could be useful to 
select--or to exclude, depending on the scientific com- 
mittee decision--patients at high risk of active disease 
which could rapidly lead to severe lesions. It has been 
shown by some authors that fingers joints with increased 
uptake were often subject to such a deterioration. ~3,14 
However, this procedure might be difficult and costly, and at 
present, the exact percentage of patients with increased 
uptake who will develop a rapidly progressive disease is 
not known. The high cost of this procedure may preclude its 
use in clinical trials. 
Outcome measures  
The primary efficacy criterion should be the radiographic 
course of hand OA over 2-5 years. One accurate method 
was that developed by Buckland-Wright et aL 7'~4'~5 They 
showed an increase in JS width of DIP and PIP joints in 
patients with early OA compared to healthy controls (over- 
hydratation?). In 33 hand OA patients, JS width did not 
change enough over an 18-month period to be considered 
a significant parameter. The two significant changes were 
those of osteophytes and of juxtaarticular adiolucencies. 
However, the special device with microfocus X-ray source 
necessary to perform macroradiographs to conduct such a 
study is available only in London. 
Harris et aL have noted over 10 years that 45-50% of 
DIP, PIP and MCP OA joints deteriorated, while about 45% 
did not change and 6-9% improved. 16 However, such long 
term follow-up is not feasible for a clinical trial. The same 
remark applies to the 6-7 year duration study by Kallman 
et aL ~'~8 who developed a complete and sensitive grading 
scale to study the radiographic progression of hand OA. 
This methodology still requires further studies to assess the 
other metrologic properties (i.e. clinical relevance, repro- 
ducibility, easiness to perform, etc.). Their global score 
sums the assessment of six radiographic features (osteo- 
phyte size, JS narrowing, subchondral bone sclerosis, 
subchondral cysts, presence of erosion, deformity) for the 
DIP, PIP, TMC and scaphotrapezial joints (only five and 
three signs graded for the two latter locations, respect- 
ively). In our experience, it takes-7-8 min for a trained 
reader to score one radiograph. 
In addition to the classic Kellgren and Lawrence 5-grade 
radiographic assessment, ~9 another feasible method 
implemented in a prospective randomized clinical trial is 
that of Verbruggen and Veys. 2°.21 In a 5-year follow-up, 
36 patients with hand OA were screened for the eight DIP, 
eight PIP (thumb excluded) and eight MCP per hand. The 
authors noted that only time frames of 3 and 5 years were 
relevant to observe significant changes. Osteophytes, 
JS and subchondral cysts were quantified as shown in 
Table III. Scores for each of the three parameters were 
combined. Two parameters exhibited significant increases 
at 3 and 5 years: the combined score adding each item of 
Table III, i.e. the worsening of lesions, and the number of 
DIP, PIP and MCP joints affected by OA in comparison with 
baseline. Moreover, the authors showed that 30-40% of 
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Table Ill 
Scores attributed to changes in osteoarthritic joints (from Verbruggen and Veys, with permission) 2° 
Osteophytes* Joint space Subchondral cysts 
Appearance + 1.0 Narrowing + 1.0 Appearance + 1.0 
Disappearance - 1.0 Widening - 1.0 Disappearance . - 1.0 
Increase in size +0.5 Increase in size +0.5 
Decrease in size -0.5 Decrease in size -0.5 
*Small ossification centers at the joint margins were regarded as OA-related changes and they were evaluated 
as osteophytes. 
their patients developed an erosive OA of some joints, a 
phase followed by reparative changes, either remodeling or 
leading to fusion. 2°'21 
Looking at the current proposed radiological methods to 
assess structure irt hand OA, five methods should be 
considered: (1) Kellgren-Lawrence score; (2) Kallman 
grading scale; (3) Verbruggen numerical scoring methods; 
(4) Buckland-Wright macroradiography and (5) global 
assessment of the presence/absence of OA. No study thus 
far has compared the respective value of the measures 
provided with these methods. One study conducted by one 
of us (Maheu et al.) is in progress, but the results are not 
yet available. For this reason we are not able, at present, to 
recommend a particular method based on documented 
evidence. We can give only an overview of each method 
and refer the reader to the paper on radiographic assess- 
ment in this issue. Further studies should elucidate the 
most appropriate radiographic method to be used in studies 
assessing the structure-modifying effects of a drug in 
hand OA. 
In the above methodologies, individual data on the TMC 
joint is not evaluated. We think that this particular location, 
where OA is very common and is usually associated with 
more pain and/or discomfort than in DIP and PIP joints, 
should have separate clinical and radiological outcome 
measures. Consequently, the TMC joint should perhaps be 
characterized separately from IP joints with OA in future 
clinical trials. 
Similarly to hip and knee OA, radiographs of the hands 
should be read blindly by one or two readers previously 
identified as having a good intrareader reproducibility. 
Films should be blinded for names and dates, and read in 
series of 20-30, each series containing in random order, all 
the radiographs for one given patientJ 
Conclusion 
Hand OA deserves to be used for therapeutic trials since 
(1) patients' demand for treatment is large; (2) it might not 
be possible to extrapolate results of trials from hip/knee OA 
to hand OA, which often progresses differently; (3) we 
currently have at our disposal a number of specific tools 
and assessment methods in hand OA which allow us to 
consider the hand as a valuable 'model' to study treatments 
for OA. These tools and methods are sensitive and provide 
an acceptable accuracy (even radiologically in the long- 
term) to lead to conclusive results. The above methodologi- 
cal propositions are obviously opened to discussion and 
should lead to the constitution of a working group and to an 
international consensus meeting. 
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